RxDoctor Payments DataLook up a doctor →

Eric Buller, PA

Medical · Lafayette, LANPI 1467423509

Payments from drug & device makers

$5,775in general payments, 2019–2025

Across 303 payments — averaging $19.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$555
  • Novartis$543
  • AstraZeneca$454
  • Daiichi Sankyo Inc.$352
  • Johnson & Johnson$334
  • E.r. Squibb & Sons, L.L.C.$317
  • plus $3K from 46 others

What the payments were for

  • Food & beverage$5,67698%
  • Education$992%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,775 in reported general payments places this provider in the 90th percentile of 253 medical providers in Louisiana.

See all medical providers in Louisiana

Medicare billing

Part B allowed, 2024
$37,851
Medicare patients
248
Services billed
539

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CalquenceAcalabrutinib Maleate25$378,802
Lenalidomide19$284,245
RevlimidLenalidomide16$262,216
BrukinsaZanubrutinib16$230,729
Imatinib Mesylate28$139,782
PromactaEltrombopag Olamine11$74,059
XareltoRivaroxaban45$30,042
EliquisApixaban22$17,767
Letrozole164$3,251
Buprenorphine12$2,918
Exemestane36$2,340
Ibandronate Sodium73$2,135
Anastrozole143$2,052
Megestrol Acetate21$717
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen17$642

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence$454$378,80225 claims
Bristol Myers SquibbRevlimid$178$262,21616 claims
Beigene USA, Inc.Brukinsa$109$230,72916 claims
NovartisPromacta$543$74,05911 claims
Johnson & JohnsonXarelto$334$30,04245 claims
PfizerEliquis$301$17,76722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 253 medical providers in Louisiana.

Other medical in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →